Business
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Maj...
About this update from Cybin, Inc.
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge OpportunityNext-generation MDD drugs are driving a new era of innovation, investment, and commercial opportunity NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on traditional antidepressants that often took several weeks to start working—and didn't always help everyone. Today, drug developers are introducing a new wave of treatments designed to work faster, target different areas of the brain, and offer hope to people with treatment-resistant depression. Researchers are also exploring innovative approaches, including NMDA receptor therapies, orexin-targeting drugs, and other next-generation medicines that could significantly improve patient outcomes. Active Companies in the biotech space current developments include: Helus PharmaTM (NASDAQ: HELP) (Cboe CA: HELP), Definium Therapeutics, Inc. (NASDAQ: DFTX), Compass Pathways plc (NASDAQ: CMPS), GH Research PLC (NASDAQ: GHRS), Johnson & Johnson (NYSE: JNJ). The opportunity is also attracting billions of dollars in investment. As more people seek treatment and awareness of mental health continues to grow, the global Major Depressive Disorder treatment market is expected to increase from about $20 billion in 2026 to nearly $36 billion by 2033, reflecting strong long-term demand. At the same time, the broader global depression drugs market is projected to grow from roughly $20 billion today to more than $25 billion by 2034, fueled by new drug approvals, expanding insurance coverage, and continued innovation across the pharmaceutical industry. For investors and healthcare companies, this is one of the most exciting areas in biotechnology today. Pharmaceutical companies are racing to develop treatments that can provide faster relief, fewer side effects, and better long-term results than older antidepressants. As more breakthrough therapies move through clinical trials and toward regulatory approval, the MDD market is expected to remain a major growth opportunity for years to come. Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results Recently closed $50 million underwritten offering reinforces strong institutional i...